NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

MEDNAX, Inc. (NYSE: MD) Class Period: February 4, 2016 to July 27, 2017 Lead Plaintiff Deadline: September 10, 2018

The lawsuit alleges MEDNAX, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company's business model was not sustainable; and (2) Mednax's growth was in fact based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections.    

On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017. Then on July 28, 2017, during an earnings call, Mednax announced that the Company failed to complete any acquisitions of anesthesiologist practices during the second quarter and disclosed that any future acquisitions were unlikely. Following this news, shares of Mednax fell from a close of $56.49 on July 27, 2017, to a close of $47.73 per share the following day.

Get additional information about the MD lawsuit: http://www.kleinstocklaw.com/pslra-c/mednax-inc?wire=3

Restoration Robotics, Inc. (NASDAQGM: HAIR) Class Period: Pursuant to the IPO between October 12, 2017 and October 16, 2017 Lead Plaintiff Deadline: August 21, 2018

The complaint alleges that Restoration Robotics negligently issued untrue statements of material facts in, and omitted to state material facts required to be stated from, the Offering Materials issued in connection with the Initial Public Offering. The complaint further alleges that as a result of the materially misleading Offering Materials, the Company’s stock price was artificially inflated at the time of the IPO.

Get additional information about the HAIR lawsuit: http://www.kleinstocklaw.com/pslra-c/restorat...air?wire=3

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 to July 9, 2018 Lead Plaintiff Deadline: September 17, 2018

The complaint alleges that during the class period ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-p...inc?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com